{"qas": [{"question": "What is subject to the Orphan Drug Act?", "id": "571af9329499d21900609bc5", "answers": [{"text": "diseases involving fewer than 200,000 patients in the United States, or larger populations in certain circumstances", "answer_start": 129}], "is_impossible": false}, {"question": "What is given to companies who develop drugs for \"orphan diseases\"?", "id": "571af9329499d21900609bc6", "answers": [{"text": "tax reductions, fee waivers, and market exclusivity on that drug for a limited time (seven years), regardless of whether the drug is protected by patents", "answer_start": 426}], "is_impossible": false}, {"question": "Why are these companies rewarded?", "id": "571af9329499d21900609bc7", "answers": [{"text": "Because medical research and development of drugs to treat such diseases is financially disadvantageous", "answer_start": 282}], "is_impossible": false}, {"question": "What is a term for rare diseases in some territories?", "id": "571d2b4ddd7acb1400e4c234", "answers": [{"text": "orphan diseases", "answer_start": 52}], "is_impossible": false}, {"question": "What size of disease populations are subject to the Orphan Drug Act?", "id": "571d2b4ddd7acb1400e4c235", "answers": [{"text": "fewer than 200,000 patients", "answer_start": 148}], "is_impossible": false}, {"question": "What is one financial benefit to researching orphan drugs?", "id": "571d2b4ddd7acb1400e4c236", "answers": [{"text": "tax reductions", "answer_start": 426}], "is_impossible": false}, {"question": "What is the length of time of market exclusivity of an orphan drug?", "id": "571d2b4ddd7acb1400e4c237", "answers": [{"text": "seven years", "answer_start": 511}], "is_impossible": false}, {"plausible_answers": [{"text": "diseases involving fewer than 200,000 patients in the United States, or larger populations in certain circumstances", "answer_start": 129}], "question": "What is subject to patients in the United States?", "id": "5ad3a4c6604f3c001a3fea95", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "tax reductions, fee waivers, and market exclusivity on that drug for a limited time (seven years), regardless of whether the drug is protected by patents", "answer_start": 426}], "question": "What is given to companies who develop rules for \"orphan diseases\"?", "id": "5ad3a4c6604f3c001a3fea96", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "Because medical research and development of drugs to treat such diseases is financially disadvantageous", "answer_start": 282}], "question": "Why are these rules rewarded?", "id": "5ad3a4c6604f3c001a3fea97", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "orphan diseases", "answer_start": 52}], "question": "What is a term for rare rules in some territories?", "id": "5ad3a4c6604f3c001a3fea98", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "fewer than 200,000 patients", "answer_start": 148}], "question": "What size of disease populations are subject to patents?", "id": "5ad3a4c6604f3c001a3fea99", "answers": [], "is_impossible": true}], "context": "C\u00f3 nh\u1eefng quy t\u1eafc \u0111\u1eb7c bi\u1ec7t cho m\u1ed9t s\u1ed1 b\u1ec7nh hi\u1ebfm g\u1eb7p (&quot; <a3_0><b10_0> b\u1ec7nh m\u1ed3 c\u00f4i <b10_0/><a3_0/> &quot;) \u1edf m\u1ed9t s\u1ed1 l\u00e3nh th\u1ed5 qu\u1ea3n l\u00fd thu\u1ed1c l\u1edbn. V\u00ed d\u1ee5: <a0_0><b7_0> b\u1ec7nh li\u00ean quan \u0111\u1ebfn <a4_0><b11_0> \u00edt h\u01a1n 200.000 b\u1ec7nh nh\u00e2n <b11_0/><a4_0/> \u1edf Hoa K\u1ef3 ho\u1eb7c s\u1ed1 l\u01b0\u1ee3ng l\u1edbn h\u01a1n trong m\u1ed9t s\u1ed1 tr\u01b0\u1eddng h\u1ee3p nh\u1ea5t \u0111\u1ecbnh <b7_0/><a0_0/> ph\u1ea3i tu\u00e2n theo \u0110\u1ea1o lu\u1eadt v\u1ec1 ma t\u00fay tr\u1ebb m\u1ed3 c\u00f4i. <a2_0><b9_0> B\u1edfi v\u00ec nghi\u00ean c\u1ee9u y h\u1ecdc v\u00e0 ph\u00e1t tri\u1ec3n c\u00e1c lo\u1ea1i thu\u1ed1c \u0111\u1ec3 \u0111i\u1ec1u tr\u1ecb c\u00e1c b\u1ec7nh nh\u01b0 v\u1eady l\u00e0 b\u1ea5t l\u1ee3i v\u1ec1 m\u1eb7t t\u00e0i ch\u00ednh <b9_0/><a2_0/> , c\u00e1c c\u00f4ng ty l\u00e0m nh\u01b0 v\u1eady \u0111\u01b0\u1ee3c khen th\u01b0\u1edfng <a1_0><a5_0><b8_0> gi\u1ea3m thu\u1ebf <a5_0/> , mi\u1ec5n l\u1ec7 ph\u00ed v\u00e0 t\u00ednh \u0111\u1ed9c quy\u1ec1n c\u1ee7a th\u1ecb tr\u01b0\u1eddng \u0111\u1ed1i v\u1edbi lo\u1ea1i thu\u1ed1c \u0111\u00f3 trong m\u1ed9t kho\u1ea3ng th\u1eddi gian gi\u1edbi h\u1ea1n ( <a6_0> b\u1ea3y n\u0103m <a6_0/> ), b\u1ea5t k\u1ec3 thu\u1ed1c c\u00f3 \u0111\u01b0\u1ee3c b\u1ea3o v\u1ec7 b\u1edfi b\u1eb1ng s\u00e1ng ch\u1ebf hay kh\u00f4ng <b8_0/><a1_0/> ."}